Roth Capital Estimates Clene’s FY2027 Earnings (NASDAQ:CLNN)

Clene Inc. (NASDAQ:CLNN) – Roth Capital boosted their FY2027 earnings per share estimates for Clene in a report released on Monday, March 24th. Roth Capital analyst J. Aschoff now forecasts that the company will post earnings per share of $6.41 for the year, up from their previous estimate of $6.30. The consensus estimate for Clene’s current full-year earnings is ($5.19) per share. Roth Capital also issued estimates for Clene’s FY2028 earnings at $9.04 EPS and FY2029 earnings at $12.47 EPS.

Clene (NASDAQ:CLNN) last issued its quarterly earnings data on Monday, March 24th. The company reported ($1.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.21) by ($0.46). Clene had a negative net margin of 8,556.77% and a negative return on equity of 1,106.30%. The business had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.13 million.

Several other research analysts have also issued reports on CLNN. HC Wainwright reaffirmed a “buy” rating and set a $31.00 target price on shares of Clene in a research report on Monday. D. Boral Capital reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Clene in a research note on Monday. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $55.25.

Clene Stock Performance

CLNN stock opened at $3.18 on Wednesday. Clene has a 52-week low of $3.09 and a 52-week high of $9.20. The company has a market capitalization of $26.48 million, a P/E ratio of -0.60 and a beta of 0.27. The company has a fifty day moving average price of $4.46 and a 200-day moving average price of $4.87.

Institutional Investors Weigh In On Clene

A number of hedge funds have recently added to or reduced their stakes in the business. Fullcircle Wealth LLC bought a new position in shares of Clene during the 4th quarter worth approximately $69,000. SBI Securities Co. Ltd. bought a new position in Clene during the fourth quarter worth $69,000. Renaissance Technologies LLC acquired a new stake in Clene in the fourth quarter worth $96,000. Geode Capital Management LLC raised its holdings in shares of Clene by 52.9% during the fourth quarter. Geode Capital Management LLC now owns 65,112 shares of the company’s stock valued at $346,000 after purchasing an additional 22,539 shares during the period. Finally, Parsons Capital Management Inc. RI bought a new position in shares of Clene during the 4th quarter worth about $194,000. 23.28% of the stock is currently owned by institutional investors.

About Clene

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.